Yesterday IntelGenx Corp (OTCMKTS:IGXT) announced that it signed definitive supple and licensing agreement with an unnamed licensed men’s health firm for two products that it is working on.
The agreement is connected to the commercialisation and co-development of the Tadalafil oral films that is meant for treating erectile dysfunction and benign prostatic hyperplasia (BPH). The company is working on the development of the product with Aquestive Therapeutics Inc. The announcement made by the company yesterday was a vital one but it did not lead to any optimism from investors. The IntelGenx stock actually declined by as much as 4% after the announcement and it remains to be seen if it can make a recovery today.
The Chief Executive Officer of the company Dr Horst G Zerbe spoke about the partnership agreement as well. He stated that securing the particular agreement was a significant milestone for IntelGenx and market another step in the right direction when it comes to its partnership with Aquestive Therapeutics. At this point in time, it might be a good idea for investors to keep an eye on any news with regards to the progress of this particular project over the course of the coming weeks.
